GILD

123.84

1.05% -1.32

시간 외 거래: 124.01 0.17 +0.14%

길리어드 사이언스 (GILD)

개요 뉴스 가격 이력 옵션 체인 Financials GILD 왜 하락? 토론 예측 주식 분할 배당 이력

전일 마감가:

$125.16

열려 있는:

$125.27

하루 거래량:

7.25M

Relative Volume:

1.09

시가총액:

$153.76B

수익:

$29.79B

순이익/손실:

$9.22B

주가수익비율:

16.85

EPS:

7.3494

순현금흐름:

$10.23B

1주 성능:

+0.06%

1개월 성능:

-7.83%

6개월 성능:

-1.46%

1년 성능:

+16.91%

1일 변동 폭

$123.67

$126.95

1주일 범위

$123.00

$127.27

52주 변동 폭

$105.79

$157.29

길리어드 사이언스 Stock (GILD) Company Profile

명칭

Gilead Sciences Inc

부문

Healthcare (1101)

산업

Drug Manufacturers - General (20)

전화

(650) 574-3000

주소

333 LAKESIDE DR, FOSTER CITY, CA

직원

17,000

트위터

@GileadSciences

다음 수익 날짜

2026-08-06

최신 SEC 제출 서류

GILD's Discussions on Twitter

Compare GILD vs LLY, JNJ, ABBV, MRK, NVS

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
GILD Gilead Sciences Inc	123.84	155.39B	29.79B	9.22B	10.23B	7.3494
LLY Lilly Eli Co	1,127.69	996.31B	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	244.88	580.14B	96.36B	21.04B	17.80B	8.6488
ABBV Abbvie Inc	243.14	415.00B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	125.45	297.86B	65.51B	8.93B	14.12B	3.5532
NVS Novartis Ag Adr	155.12	292.17B	54.66B	13.58B	16.05B	7.0171

길리어드 사이언스 Stock (GILD) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-03-10	개시	Jefferies	Buy
2026-02-20	개시	Barclays	Equal Weight
2026-02-11	재확인	Needham	Buy
2026-01-07	재개	UBS	Buy
2025-11-24	재개	Truist	Buy
2025-11-13	개시	Scotiabank	Sector Outperform
2025-08-19	업그레이드	Daiwa Securities	Neutral → Outperform
2025-08-08	업그레이드	Truist	Hold → Buy
2025-07-25	업그레이드	Needham	Hold → Buy
2025-04-22	재개	Cantor Fitzgerald	Overweight
2025-03-04	재확인	Oppenheimer	Outperform
2025-02-18	업그레이드	Deutsche Bank	Hold → Buy
2025-02-13	업그레이드	DZ Bank	Hold → Buy
2025-01-10	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	재개	BofA Securities	Buy
2024-11-15	개시	Wolfe Research	Outperform
2024-11-14	개시	Citigroup	Buy
2024-11-08	다운그레이드	Maxim Group	Buy → Hold
2024-10-21	업그레이드	Leerink Partners	Market Perform → Outperform
2024-10-17	개시	Bernstein	Outperform
2024-10-07	업그레이드	Wells Fargo	Equal Weight → Overweight
2024-07-08	업그레이드	Raymond James	Mkt Perform → Outperform
2024-05-01	재확인	Maxim Group	Buy
2024-04-24	업그레이드	HSBC Securities	Reduce → Hold
2024-02-22	다운그레이드	Truist	Buy → Hold
2023-11-09	개시	Deutsche Bank	Hold
2023-09-08	업그레이드	BofA Securities	Neutral → Buy
2023-09-06	개시	HSBC Securities	Reduce
2023-07-24	재확인	Barclays	Equal Weight
2023-05-16	업그레이드	BMO Capital Markets	Market Perform → Outperform
2023-04-28	재개	Piper Sandler	Overweight
2023-01-03	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2022-12-13	재개	BofA Securities	Neutral
2022-12-09	다운그레이드	DZ Bank	Buy → Hold
2022-10-31	업그레이드	Barclays	Underweight → Equal Weight
2022-10-28	재확인	BMO Capital Markets	Market Perform
2022-10-28	재확인	Cowen	Outperform
2022-10-28	재확인	JP Morgan	Overweight
2022-10-28	재확인	Jefferies	Buy
2022-10-28	업그레이드	Piper Sandler	Neutral → Overweight
2022-10-28	재확인	RBC Capital Mkts	Outperform
2022-10-28	업그레이드	Truist	Hold → Buy
2022-10-28	재확인	Wells Fargo	Equal Weight
2022-10-04	업그레이드	JP Morgan	Neutral → Overweight
2022-07-13	개시	Cantor Fitzgerald	Neutral
2022-05-23	개시	SVB Leerink	Mkt Perform
2022-02-28	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2022-02-02	재확인	BMO Capital Markets	Outperform
2022-02-02	재확인	BofA Securities	Neutral
2022-02-02	재확인	RBC Capital Mkts	Outperform
2022-02-02	재확인	Truist	Hold
2022-02-02	재확인	Wells Fargo	Equal Weight
2022-01-28	업그레이드	Argus	Hold → Buy
2022-01-06	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2021-12-09	재개	Wells Fargo	Equal Weight
2021-12-06	개시	Goldman	Neutral
2021-11-19	업그레이드	BMO Capital Markets	Market Perform → Outperform
2021-11-19	재개	Piper Sandler	Neutral
2021-10-20	재개	Cowen	Outperform
2021-07-30	재확인	BMO Capital Markets	Market Perform
2021-07-30	재확인	RBC Capital Mkts	Outperform
2021-04-01	업그레이드	Bernstein	Mkt Perform → Outperform
2021-03-30	업그레이드	Redburn	Neutral → Buy
2021-01-19	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2021-01-04	업그레이드	Guggenheim	Neutral → Buy
2020-11-03	재개	Morgan Stanley	Equal-Weight
2020-10-28	개시	UBS	Neutral
2020-09-30	재개	Jefferies	Buy
2020-09-15	업그레이드	Maxim Group	Hold → Buy
2020-07-31	재확인	Credit Suisse	Neutral
2020-07-31	재확인	Morgan Stanley	Equal-Weight
2020-07-31	재확인	Piper Sandler	Overweight
2020-07-31	재확인	RBC Capital Mkts	Outperform
2020-07-31	재확인	SunTrust	Hold
2020-07-31	재확인	Wells Fargo	Equal Weight
2020-07-20	업그레이드	Credit Suisse	Underperform → Neutral
2020-06-03	업그레이드	SVB Leerink	Mkt Perform → Outperform
2020-05-26	업그레이드	SunTrust	Sell → Hold
2020-05-01	다운그레이드	JP Morgan	Overweight → Neutral
2020-05-01	다운그레이드	Raymond James	Outperform → Mkt Perform
2020-05-01	다운그레이드	SunTrust	Hold → Sell
2020-04-27	다운그레이드	UBS	Buy → Neutral
2020-04-20	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2020-04-20	다운그레이드	Wells Fargo	Overweight → Equal Weight
2020-04-17	다운그레이드	CFRA	Hold → Sell

모두보기

길리어드 사이언스 주식(GILD)의 최신 뉴스

Jun 25, 2026

Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know - Yahoo Finance UK

Jun 25, 2026

Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer - Benzinga

Jun 25, 2026

Gilead Sciences updates oncology pipeline, shares steady on NASDAQ - Ad-hoc-news.de

Jun 25, 2026

Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use - Yahoo Finance Singapore

Jun 25, 2026

Gilead’s TROP-2 Trodelvy, Keytruda combo win first-line FDA nods for breast cancer - BioSpace

Jun 25, 2026

New FDA Nod Keeps Gilead Drug Competitive With AstraZeneca & Daiichi in Breast Cancer - MedCity News

Jun 25, 2026

Jun 24, 2026

Gilead Says FDA Approves Trodelvy for First-Line Treatment of Advanced Triple-Negative Breast Cancer - marketscreener.com

Jun 24, 2026

GILD Receives FDA Approval for Trodelvy in Triple-Negative Breas - GuruFocus

Jun 24, 2026

FDA approves Gilead’s Trodelvy for first-line breast cancer By Investing.com - Investing.com Canada

Jun 24, 2026

Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) and Gilead Sciences (GILD) - The Globe and Mail

Jun 24, 2026

Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC - Yahoo Finance Singapore

Jun 24, 2026

Astellas Padcev and Gilead's Trodelvy grab key EU approvals - pharmaphorum

Jun 24, 2026

5 Set-It-and-Forget-It Stocks to Buy Right Now - Insider Monkey

Jun 24, 2026

Jun 23, 2026

Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh Trade Ideas — BCBA:GILD.CI - TradingView

Jun 23, 2026

Gilead Sciences highlights ongoing commitment to Pride, inclusion in community and workplace - ABC7 Bay Area

Jun 23, 2026

Gilead receives EU nod for Trodelvy in first-line metastatic triple-negative breast cancer - grafa.com

Jun 23, 2026

GILD Gains EU Approval for Trodelvy in Treating Triple-Negative Breast Cancer - GuruFocus

Jun 23, 2026

Gilead Sciences: The Market Is Underestimating Its Growth Runway (NASDAQ:GILD) - Seeking Alpha

Jun 23, 2026

Gilead’s Trodelvy wins EU approval for first-line breast cancer - Investing.com

Jun 23, 2026

Gilead Sciences Receives EU Marketing Approval for Trodelvy as Breast Cancer Treatment - marketscreener.com

Jun 23, 2026

Gilead Sciences draws Cantor support, shares sit below $155 target - AD HOC NEWS

Jun 23, 2026

Jun 22, 2026

Jared Moskowitz from Florida’s 23rd District Trades in Cencora and Gilead Sciences Stocks - Investing.com Canada

Jun 22, 2026

Cantor Fitzgerald reiterates Gilead Sciences stock Overweight rating at $155 - Investing.com UK

Jun 22, 2026

Gilead Sciences wins FDA backing for weekly HIV pill, Cantor sticks to Overweight call on the shares - AD HOC NEWS

Jun 22, 2026

Gilead Sciences Stock (GILD) Opinions on Recent Congressional Insider Activity - Quiver Quantitative

Jun 22, 2026

Could This FDA Milestone Unlock Gilead’s (GILD) Next Big Growth Driver? - Insider Monkey

Jun 22, 2026

Cantor Fitzgerald reiterates Gilead Sciences stock Overweight rating at $155 By Investing.com - Investing.com Canada

Jun 22, 2026

Jun 20, 2026

How Investors May Respond To Gilead Sciences (GILD) FDA Review Of Once‑Weekly Oral HIV PrEP - Sahm

Jun 20, 2026

Jun 19, 2026

Gilead Sciences (GILD) Gets a Buy from Scotiabank - The Globe and Mail

Jun 19, 2026

Jun 18, 2026

Gilead Sciences stock price forecast: $120.19 support in focus as GILD slides 1.82% - Traders Union

Jun 18, 2026

GILD News | GILEAD SCIENCES INC (NASDAQ:GILD) - ChartMill

Jun 18, 2026

Gilead’s Work to Help End the HIV Epidemic, One Year after Launch of its Twice-Yearly Prevention Medication - Gilead Sciences

Jun 18, 2026

Vascular Dementia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | Pfizer, Gilead Sciences, ViiV Healthcare - Barchart.com

Jun 18, 2026

Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch

Jun 18, 2026

Gilead Sciences Cell Therapy Move Draws Biotech Attention - Kalkine Media

Jun 18, 2026

Gilead Sciences StockFDA accepts filing for weekly HIV prevention pill - AD HOC NEWS

Jun 18, 2026

World Economic Forum, Takeda and Gilead executives confirmed for Women's HealthX in Boston - FemTech World

Jun 18, 2026

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - Yahoo Finance

Jun 18, 2026

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance

Jun 18, 2026

Jun 17, 2026

Why Gilead Sciences bets on Sunlenca as a long-acting HIV anchor - AD HOC NEWS

Jun 17, 2026

Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Jun 17, 2026

Pharma Giants Navigate A Busy Deal-Making Backdrop - Kalkine Media

Jun 17, 2026

Gilead Sciences (GILD) Donates Remdesivir to Uganda - Insider Monkey

Jun 17, 2026

Gilead Sciences Inc (GILD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 17, 2026

Voya Global High Dividend Low Volatility Portfolio's Gilead Sciences Inc(GILD) Holding History - GuruFocus

Jun 17, 2026

Gilead Sciences (GILD) Receives a Buy from Citi - The Globe and Mail

Jun 17, 2026

Analysts Are Bullish on These Healthcare Stocks: Irhythm Technologies (IRTC), Gilead Sciences (GILD) - The Globe and Mail

Jun 17, 2026

The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK - The Globe and Mail

Jun 17, 2026

Jun 16, 2026

Gilead Sciences chief comm officer sells $371k in stock - Investing.com UK

Jun 16, 2026

[Press release] FDA accepts Gilead’s application for investigational once-weekly oral Yeztugo, potentially the first long-acting pill for HIV prevention - European AIDS Treatment Group

Jun 16, 2026

Gilead Sciences chief comm officer sells $371k in stock By Investing.com - Investing.com Nigeria

Jun 16, 2026